ClinicalTrials.Veeva

Menu

Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer

S

ShangHai Ji Ai Genetics & IVF Institute

Status and phase

Unknown
Phase 4

Conditions

Clomiphene Citrate
Infertility, Female

Treatments

Drug: Clomiphene Citrate protocol
Procedure: Procedure

Study type

Interventional

Funder types

Other

Identifiers

NCT03309436
JIAI E2017-11

Details and patient eligibility

About

Clomiphene citrate has been widely used for treatment of infertility for decades. Although its anti-estrogenic effects leads to low pregnancy rate, clomiphene citrate is still a first-line treatment for ovulation induction because of its simple usage, low prices, no injection and low risk of ovarian hyperstimulation syndrome. Clomiphene citrate shows high affinity with estrogen receptor, which inhibits endometrial proliferation, inevitably leads to a decline in endometrial receptivity, thus affecting the success rate of IVF.

In that case, use clomiphene citrate for ovulation induction is lost more than gained based on fresh embryo transfer. But recently, some researchers have proposed to extend the time from ovulation induction to embryo transfer, and the increased level of estradiol can replace clomiphene citrate to combine with the receptor, so that the uterine environment is more conducive to pregnancy. Therefore, use clomiphene citrate based on vitrification of embryo maybe a good way for treatment of infertility.

At present, using frozen embryo transplantation after ovulation induction by clomiphene citrate is a common treatment, but few research has mentioned the best time for embryo implantation. The investigators research is to find the most appropriate time for frozen embryo implantation after using clomiphene citrate for ovulation induction.

Full description

This study receives patients from 2017 August to 2018 June who undergo ART treatment at Shanghai Jiai Genetics & IVF Institute and taken either CC or GnRH antagonist protocol(control group) for ovulation induction.

The investigators will record every patients' age, BMI, serum E2, P, LH level, infertility factors and pregnancy outcomes, counted the implantation rate and clinical pregnancy rate, and then used SPSS Software x2 test for statistical analysis, the significance was set at p<0.05.The investigators will also make a correlation analysis about the serum hormone level and pregnancy outcomes.

Enrollment

360 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women 18-40 years of age who are scheduled for IVF or ICSI in our IVF institute while meeting the following criteria:

  1. AMH ≥ 2;
  2. Infertility factors: tubal factor, severe oligospermia, etc;
  3. FET cycle;
  4. Cleavage stage embryo transfer (Day 3).

Exclusion criteria

  1. BMI ≤ 18.4 or ≥ 25.0;
  2. Have pregnancy complications;
  3. Genital tract malformations, uterine cavity diseases, PCOS;
  4. Endometriosis;
  5. Genetic diseases, severe somatic diseases, mental disorder.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

360 participants in 2 patient groups

Use Clomiphene Citrate protocol
Experimental group
Description:
Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
Treatment:
Drug: Clomiphene Citrate protocol
Procedure
Active Comparator group
Description:
Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
Treatment:
Procedure: Procedure

Trial contacts and locations

1

Loading...

Central trial contact

YINING XU, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems